Dr. Gary Remington is a senior scientist and chief of the Schizophrenia Division at the Centre for Addiction and Mental Health (CAMH). He is also a professor of psychiatry at the University of Toronto.
Areas of Research
Dr. Remington’s research focus is on the pharmacotherapy of schizophrenia, particularly as it applies to the pharmacology and clinical profile of new antipsychotics and decision-making in antipsychotic therapy. He is currently part of a working group at the University of Toronto where the concentration has been on the role of dopamine, using in vitro (receptor binding), in vivo (PET), preclinical, and human clinical studies. Dr. Remington is also conducting clinical trials to study pharmacological strategies that might include clinical response, as well as assist in the management of antipsychotic-related side-effects.
View Dr. Remington's publications on PubMed.